UroMems Appoints Rinda Sama, Former Axonics Executive, to Board of Directors

UroMems Welcomes Rinda Sama to Its Board of Directors

UroMems, a global leader in medical technology, has announced the appointment of Rinda Sama, a seasoned executive from Axonics, to its board of directors. This decision comes at a critical time as UroMems gears up for significant clinical trials for its groundbreaking UroActive system, designed to treat stress urinary incontinence (SUI).

Enhancing Expertise for Clinical Trials

Rinda Sama brings nearly two decades of invaluable experience in the medical device field. Previously the Chief Operating Officer at Axonics, she played a pivotal role in optimizing operational processes which were instrumental in achieving FDA approvals and the recent acquisition of Axonics by Boston Scientific. Her appointment is expected to significantly bolster UroMems’s readiness for clinical trials in both the United States and Europe, ultimately leading to the commercial launch of the first automated intelligent artificial urinary sphincter (AUS).

Hamid Lamraoui, co-founder and CEO of UroMems, expressed enthusiasm about Sama's leadership. He stated, “With Rinda’s extensive background in medical technology and her experience particularly in sacral neuromodulation therapy to treat overactive bladder, her insights will be vital as we move into pivotal clinical trials.”

UroActive: A Revolutionary Approach

UroActive represents the first robotic-assisted AUS designed to counteract sphincter insufficiency in both men and women suffering from SUI. Leveraging a unique mechatronic platform that employs integrated intelligent, digital, and robotic systems, UroActive personalizes treatment algorithms based on individual patient data, safeguarding safety and enhancing performance. Currently, UroActive is protected by over 150 patents and aims to remedy longstanding issues associated with existing treatments. However, as of now, it has yet to receive FDA market authorization and isn't available for sale in the United States or Europe.

The condition of SUI affects approximately 40 million Americans and 90 million Europeans, severely impacting their lives and often leading to depression, low self-esteem, and social stigma. UroMems's innovative approach is particularly promising, offering hope to those poorly served by current solutions.

Anticipation for Future Progress

As UroMems achieves crucial R&D milestones—including a recent $47 million funding boost related to outstanding clinical results—Sama’s expertise in navigating the path toward FDA approval positions UroMems advantageously. She commented on the opportunity at UroMems: “This company stands at a similar juncture to where Axonics was years ago, developing a game-changing treatment option following decades of limited innovation in the field. I see tremendous potential in UroActive to revolutionize the way stress urinary incontinence is treated.”

Conclusion

With Rinda Sama now part of its leadership team, UroMems is poised to make significant strides in the medical technology landscape, specifically in treating stress urinary incontinence. Her operational insights, alongside the groundbreaking technology of UroActive, may very well alter the treatment trajectory for this prevalent condition.

For more information about UroMems and their innovative projects, visit UroMems Website.